Search Results

Eilean Therapeutics AU Pty Ltd has joined The Leukemia & Lymphoma Society in the groundbreaking collaborative Beat AML® Master Clinical Trial.

The Leukemia & Lymphoma Society named five new members to its board of directors effective July 1, 2024, whose diverse experience and interests will be instrumental in helping the organization carry out its mission to cure blood cancer and improve the quality of life of all patients and their families.

The Leukemia & Lymphoma Society®, a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced a collaboration to accelerate blood cancer research.

The Leukemia & Lymphoma Society’s Equity in Access Research Program announced the opening of its application process for the 2025 funding cycle.

Jasper Health is proud to announce a strategic collaboration with The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer.

Rgenta Therapeutics announced that it was selected by The Leukemia & Lymphoma Society as a new Therapy Acceleration Program® portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company’s therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) announced an agreement to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy for leukemia and lymphoma.

More people than ever need the resources and research that The Leukemia & Lymphoma Society provides and funds.

Enterome announced that it received a €3 million investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program®.